44 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27997164	18	Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting thea	Universit£
27774126	95	Exploring	University of California San Francisco
24949551	22	Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.	Philipps-Universit£T Marburg
24654918	19	Pharmacophoric modifications lead to superpotentavß3 integrin ligands with suppresseda5ß1 activity.	Technische Universit£T M£Nchen
23362923	59	Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids.	Technische Universit£T M£Nchen
19959360	50	SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.	Jerini
19910191	46	Discovery of orally available integrin alpha5beta1 antagonists.	Jerini
23140358	28	Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrinaVß3.	Universit£
22959246	24	Camptothecins in tumor homing via an RGD sequence mimetic.	Sigma-Tau Industrie Farmaceutiche Riunite
18343671	8	Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands.	Department of Organic Chemistry Ugo Schiff University of Firenze Via Della Lastruccia 13
18303826	48	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.	Universit£
17184884	16	Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.	Johnson & Johnson Pharmaceutical Research and Development
16302808	28	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.	Universit£
15357991	20	Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.	3-Dimensional Pharmaceuticals
20809642	28	Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis.	University of Florence
19942441	47	Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation.	Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni
17616113	63	Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.	Jerini
17387018	74	Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.	Pfizer
16621534	87	Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists.	Pfizer
16509596	29	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior.	Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni
16298127	80	Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.	Pfizer
15715463	16	Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.	Johnson and Johnson Pharmaceutical Research & Development
15501072	58	1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.	Johnson & Johnson Pharmaceutical Research & Development
15006384	179	Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonists.	Pfizer
12668017	17	Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.	Glaxosmithkline
12565960	33	Thiophene-based vitronectin receptor antagonists.	Shire Biochem
12482416	52	Highly potent and selective alphaVbeta3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones.	Basf
12392735	30	Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.	Institut De Recherches Servier
11855984	102	Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.	Merck
32094009	36	Novel cilengitide-based cyclic RGD peptides as ?v?	Division of Organic Chemistry Csir-National Chemical Laboratory (Ncl)
30657681	262	Selective Targeting of Integrin ?v?8 by a Highly Active Cyclic Peptide.	Technische Universit£T M£Nchen
10406646	15	Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.	Smithkline Beecham Pharmaceuticals
31381331	70	Profile of a Highly Selective Quaternized Pyrrolidine Betaine ?	Glaxosmithkline Medicines Research Centre
25721024	4	In silico studies, synthesis and binding evaluation of substituted 2-pyrrolidinones as peptidomimetics of RGD tripeptide sequence.	Universit£
24568695	76	Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.	University of Bradford
25408832	152	Structure Activity Relationships of ?v Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents.	University of Nottingham
7507165	139	Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.	Telios Pharmaceuticals
30215258	228	Discovery of ( S)-3-(3-(3,5-Dimethyl-1 H-pyrazol-1-yl)phenyl)-4-(( R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic ?	University of Strathclyde
28351594	24	New potent and selective?v?	Jiangnan University